HIDDEN DANGER IN PSYCHIATRY: DRUG-INDUCED CHOLESTASIS AS AN UNDERRECOGNISED ADVERSE EFFECT

Authors

  • RENGARAJ THIRUNANAMOORTHY Department of General Medicine, Government Medical College and Hospital, Nagapattinam, Tamil Nadu, India
  • VENNILA SANKAR Department of Pharmacy Practice, E. G. S. Pillay College of Pharmacy, Nagapattinam, Tamil Nadu, India https://orcid.org/0009-0005-8882-1704
  • THASLIM RIDHWANA BARAKATH ALI Department of Pharmacy Practice, E. G. S. Pillay College of Pharmacy, Nagapattinam, Tamil Nadu, India https://orcid.org/0009-0006-2176-6437
  • PARI KUMANAN Department of Pharmacy Practice, E. G. S. Pillay College of Pharmacy, Nagapattinam, Tamil Nadu, India https://orcid.org/0009-0006-7153-1708
  • Surya R. Department of Pharmacy Practice, E. G. S. Pillay College of Pharmacy, Nagapattinam, Tamil Nadu, India

DOI:

https://doi.org/10.22159/ijpps.2025v17i10.56102

Keywords:

Drug-induced liver injury, Cholestatic liver injury, Psychiatric drugs, RUCAM, Adverse drug reactions, Pharmacovigilance

Abstract

Drug-induced liver injury (DILI) often goes overlooked due to its non-specific symptoms. If left untreated, even acute liver injury could lead to serious complications. We reported the case of a 50 y old female who presented with symptoms of acute gastroenteritis and urinary tract infection. Initially, liver function tests revealed elevated aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and bilirubin levels. The patient’s history of multiple psychiatric medications: tablet chlorpromazine, tablet olanzapine, capsule fluoxetine, and tablet diazepam, raised suspicion of DILI. The updated Roussel Uclaf Causality Assessment Method (RUCAM) scoring indicated “possible” causality for all four drugs, with chlorpromazine receiving the highest score. All psychiatric medications were discontinued, and the repeated liver function test after eight days demonstrated significant improvement. This case highlighted the importance of liver function monitoring in patients receiving psychotropic polypharmacy and underscored the value of structured causality tools such as RUCAM in guiding clinical decisions.

Downloads

Download data is not yet available.

References

1. Dey P, Saha MR, Sen A. An overview on drug-induced hepatotoxicity. Asian J Pharm Clin Res. 2013;6(4):1-4.

2. LV Q, Yi Z. Antipsychotic drugs and liver injury. Shanghai Arch Psychiatry. 2018;30(1):47-51. doi: 10.11919/j.issn.1002-0829.217090, PMID 29719358.

3. Subramaniam B, Shah M, Desai C, Panchal J, Shah S. An analysis of cases of drug-induced liver injury reported to an adverse drug reaction monitoring center. Asian J Pharm Clin Res. 2020;13(11):109-12. doi: 10.22159/ajpcr.2020.v13i11.39312.

4. Sundaram V, Bjornsson ES. Drug-induced cholestasis. Hepatol Commun. 2017;1(8):726-35. doi: 10.1002/hep4.1088, PMID 29404489.

5. Telles Correia D, Barbosa A, Cortez Pinto H, Campos C, Rocha NB, Machado S. Psychotropic drugs and liver disease: a critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther. 2017;8(1):26-38. doi: 10.4292/wjgpt.v8.i1.26, PMID 28217372.

6. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246-59. doi: 10.1053/j.gastro.2010.04.001, PMID 20394749.

7. Danan G, Teschke R. Rucam in drug and herb-induced liver injury: the update. Int J Mol Sci. 2015;17(1):14. doi: 10.3390/ijms17010014, PMID 26712744.

8. Lu LY, Tsai CC. Analysis of agomelatine treatment with depressive symptoms. Int J App Pharm. 2021;13Suppl 1:63-6. doi: 10.22159/ijap.2021.v13s1.Y0110.

Published

01-10-2025

How to Cite

THIRUNANAMOORTHY, RENGARAJ, et al. “HIDDEN DANGER IN PSYCHIATRY: DRUG-INDUCED CHOLESTASIS AS AN UNDERRECOGNISED ADVERSE EFFECT”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 17, no. 10, Oct. 2025, pp. 45-47, doi:10.22159/ijpps.2025v17i10.56102.

Issue

Section

Case Study(s)

Similar Articles

<< < 1 2 3 4 5 > >> 

You may also start an advanced similarity search for this article.